

# TABLE OF CONTENTS

June 4, 2007

No. 2043

## GENERIC

- 1 New JGPMA President H. Sawai Aims at 30% Share for Generics
  - Reasonable Prices Essential to Ensure Stable Supply
  - Generics Present No Quality-Related Problems
  - Sales Volume-Based Share of Generics Up to 17.1% in FY2005
  - Over 90% of People Want to Use Generic Drugs
- 3 *Koroshō* Proposes Switching to Generics to Lift Price Agreement Rate
- 3 Generics and Original Drugs Are Not the Same: Prof. Uchida
- 3 **GENERICNEWSINBRIEF**
  - Savings of ¥1.3 Tril. with Generics Is a Bold Hypothesis: JMA
  - Generics Must Be Listed 4 Times a Year: Mr Tsushima
- 4 **Commentary**
  - Show Road Map to the Goal – 30% Share for Generics

## BUSINESS

- 5 Four Major Wholesalers' Sales Up 10.2%, Operating Profits Up 32.8%
- 6 Mediceo Paltac: Sales Exceed ¥2 Tril. Mark
  - 97.7% Price Agreement Rate at the End of March
- 6 Alfresa HD: Sales Up 12.6% to ¥1,590 Bil., Big Jump in Profits
  - New 3-Year Plan to Focus on Self-Medication
  - CS Yakuhin, Ryuyaku Become Wholly-Owned Subsidiaries
- 7 Suzuken: Sales Up 4.8% to ¥1,455 Bil.
  - Aiming at an 11% Increase in Gross Profits on Sales
  - Entry into Chinese Market through Joint Venture
- 7 Toho Pharm.: Sales Up 9.5%, Operating Profits Up 52.9%
  - Making Greater Efforts to Eliminate Bundling
- 8 VITAL-NET: Aiming at Ordinary Profits-to-Sales Ratio of 2.2%
- 8 Hokuyaku Takeyama: ¥169 Billion Sales in Hokkaido
- 8 Ohki: Profits Hit Hard due to Greater Discounts
- 9 Otsuka: Sales Up 18.5% to ¥576.1 Bil. Driven by Strong Overseas Sales
- 9 Meiji Seika Kaisha: Pharm. Sales Down 5.0% to ¥109,668 Mil.
- 9 Tsumura: Ethical *Kampo* Medicines Offset Divestiture of Health Food Business
  - Development of TU-025 in US Discontinued
- 9 Nippon Shinyaku: Profits Up as a Result of Cost-cutting
  - Strengthening the R&D Pipeline in Urology
- 10 Zeria: Upfront Payment Boosts Profits Despite Fall in Sales
- 10 Fuso: Sales of Artificial Dialysate Hit by NHI Price Cut
- 11 ASKA: Operating Profits Increase 2.5-Fold as a Result of Merger Synergism
- 12 Yakult Honsha: Elplat Drives Sales with 78.1% Growth in Sales
- 12 Toyama Chemical: Operating Loss of ¥5.7 Bil.
- 12 Seikagaku Corp.: Overseas Markets Account for 26.3% of Sales
- 12 JCR Pharm: Net Losses for 3 Years in a Row
- 13 Sosei: Large Losses Due to Acquisition of UK Subsidiary
- 13 Nissan Chemical: Livalo Props Up Pharm. Sales
- 13 Kaigen: Sales Slip 2.6% to ¥10,871 Mil.
- 16 **BUSINESSNEWSINBRIEF**
  - NanoCarrier Develops New Protein Nanoencapsulation Technology
  - Shin-Etsu Chemical Partially Restart Manufacturing Cellulose Derivatives

- Sanofi-aventis Completes New Ampule Production Facility
- So-net M3 to Operate *MR-kun* in US

## COMMENTARY

- 14 **Maurer's Healthcare Insight (87)**
  - Japan Is (Is Not) an Attractive Market: Part 2: P. Reed Maurer
- 17 **OPINION**
  - Would You Follow Someone Like You?: Philip Carrigan

## R&D

- 17 NEJM Article on Avandia "Based on Incomplete Evidence": GSK
- 18 **R&DNEWSINBRIEF**
  - Sosei Completes PI Trial for AD 923 in the US
  - GNI Identifies Human PFTK1
  - Amlodipine + Olmesartan Combination Effective for Hypertension: Daiichi Sankyo
  - Takara Bio to Collaborate with Mie Univ. on Cancer Immunity Reconstruction Therapy
  - *Koroshō* to Abolish Requirement for an IRB at Each Institution

## REGULATORY

- 18 **REGULATORYNEWSINBRIEF**
  - FPMMA Member Orgs Asked to Present Their Views on NHI Pricing System
  - Kissei Obtains Approval for Glufast +  $\alpha$ -GI Combination
  - Bayer Yakuhin Obtains Marketing Approval for Levitra Tablet 20 mg

## MEDICAL FACILITIES & NURSING CARE

- 19 *Koroshō* Has No Plan to Cut Initial/Repeat Consultation Fees: *Koroshō* Officials
- 20 **MEDICAL FACILITIES & NURSING CARE NEWS INBRIEF**
  - Importance of Personalized Breast Cancer Treatment Increasing
  - PPI Improve QOL More than H2-blockers in Reflux Esophagitis Patients
  - *Koroshō* to Increase Number of DPC Hospitals to 1,000

## SELF-MEDICATION

- 21 **SELF-MEDICATIONNEWSINBRIEF**
  - Kobayashi Pharm.: Household Product-manufacturing Business Goes Well
  - Rohto: Record-High Sales, Profits for 3rd Year in a Row
  - SSP: Sales Down 7.7%, No Prospect of Recovery

## MEDICAL DEVICES

- 22 **MEDICALDEVICENEWSINBRIEF**
  - Nissui: TOX A/B QUIK CHEK
  - Kyowa Medex to Market 26 Products from DiaSorin
  - Sekisui to Enhance Market Presence by Reshuffling Daiichi Pure Chemicals
  - Miraca HD: Sales of Lab Test Reagents Remain Strong
  - Kawasaki Lab.: Sales Up 7.5%, Profits Jump
  - Kawamoto: Profits Fall due to Hospitals' Cost-cutting Efforts
- 22 **Survey**
  - Low Expectations for Treatment of ADHD in Japan: Eli Lilly